Cytokinetics Inc CYTK
We take great care to ensure that the data presented and summarized in this overview for CYTOKINETICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CYTK
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$604 Million0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$503 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$411 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$269 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$219 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.65MShares$125 Million4.28% of portfolio
-
Ubs Group Ag3.07MShares$105 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA2.99MShares$103 Million0.01% of portfolio
-
Vestal Point Capital, LP New York, NY2.98MShares$102 Million5.18% of portfolio
-
Polar Capital Holdings PLC London, X02.8MShares$96 Million0.53% of portfolio
Latest Institutional Activity in CYTK
Top Purchases
Top Sells
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Insider Transactions at CYTK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.29%
|
$190,000
$38.42 P/Share
|
|
Aug 05
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$72,000
$36.34 P/Share
|
|
Aug 05
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.38%
|
$20,000
$10.6 P/Share
|
|
Jul 29
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.27%
|
$180,000
$36.45 P/Share
|
|
Jul 22
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$74,000
$37.47 P/Share
|
|
Jul 22
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.38%
|
$20,000
$10.6 P/Share
|
|
Jul 15
2025
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
164
+0.53%
|
$6,232
$38.01 P/Share
|
|
Jul 15
2025
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
559
+0.75%
|
$21,242
$38.01 P/Share
|
|
Jul 15
2025
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
328
+1.43%
|
$12,464
$38.01 P/Share
|
|
Jul 15
2025
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
328
+1.08%
|
$12,464
$38.01 P/Share
|
|
Jul 15
2025
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
164
+0.5%
|
$6,232
$38.01 P/Share
|
|
Jul 14
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.26%
|
$190,000
$38.15 P/Share
|
|
Jul 08
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$66,000
$33.76 P/Share
|
|
Jul 08
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.38%
|
$20,000
$10.6 P/Share
|
|
Jul 01
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.24%
|
$165,000
$33.55 P/Share
|
|
Jun 17
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$64,000
$32.91 P/Share
|
|
Jun 17
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.38%
|
$20,000
$10.6 P/Share
|
|
Jun 16
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.23%
|
$165,000
$33.8 P/Share
|
|
Jun 05
2025
|
Edward M. Md Kaye Director |
SELL
Open market or private sale
|
Direct |
3,636
-10.92%
|
$116,352
$32.1 P/Share
|
|
Jun 05
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
8,659
-14.27%
|
$277,088
$32.04 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 366K shares |
|---|---|
| Exercise of conversion of derivative security | 202K shares |
| Open market or private sale | 411K shares |
|---|---|
| Payment of exercise price or tax liability | 16K shares |
| Bona fide gift | 2.16K shares |